Hims & Hers Health, Inc.

NYSE: HIMS·San Francisco, California·

Price
$18.56
Base IV
$10.11

Valuation snapshot

Above base case

At $18.56, the price sits between our base case ($10.11) and bull case ($21.96).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$10.11
54% of the price · range $0.92–$21.96
Price vs base case
84% above
$18.56 against $10.11
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has fallen 10.8% since this valuation was struck on 2026-11-12, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $0.92 to bull $21.96. Values per share.

Price against each value

Bear case
$0.92
Price 1,918% above
No growth
…
—
Base case
$10.11
Price 84% above
Researched byClaude Opus 5.5
Valuation Nov 12, 2026 · Price as of Nov 16, 2026How we got here

What does Hims & Hers Health do?

Hims & Hers Health provides a digital platform that connects consumers to licensed healthcare providers for prescriptions, laboratory testing, and over-the-counter wellness products for chronic conditions.

It brought in $2.9B of sales in the 12 months to Sep 2026.

Led by Andrew Dudum, Co-Founder, Chief Executive Officer and Chairman of the Board since 2016. Hims & Hers Health, Inc. – Definitive Proxy Statement (DEF 14A), 2026

Hims app for online care and personalized treatmentImage: Hims & Hers
Industry
Healthcare
Based in
San Francisco, California
Trades on
NYSE as HIMS

Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.07, so it lost 7¢ on each dollar. The biggest cost is sales, marketing and admin, 51¢ of every dollar.

$1 of sales
  • Making what it sells36¢
  • Sales, marketing and admin51¢
  • Everything else it takes to operate21¢
  • Tax credit came back in+1¢
  • Lost on each dollar−7¢
Totals of the four quarters to Sep 2026, from the company's own filings.

Who pays Hims & Hers Health, and for what?

Hims & Hers sells access to online healthcare, prescriptions and wellness products through its websites and apps. Customers can consult licensed providers, receive personalized treatment and have prescriptions fulfilled through licensed pharmacies; many products are sold on recurring subscriptions.

Consumers pay directly for products and services, mainly through the company’s websites and mobile apps.

  • United States Revenue

    Products and services sold by the company’s U.S. entities, including online care and product sales.

    Hims app for online care and personalized treatmentImage: Hims & Hers
  • Rest of the World Revenue

    Products and services sold by entities operating outside the United States.

  • Online Revenue

    Direct sales through the company’s websites and apps, mostly recurring subscriptions, with some one-time purchases.

    Hims app provider care for acne treatmentImage: Hims & Hers
  • Wholesale Revenue

    Non-prescription products sold to retailers and third-party platforms.

We don't have each line's share of sales for this company yet.

Where its work physically happens, beyond headquarters:

  • New Albany pharmacy and manufacturing campus — New Albany, United States. The company's major fulfillment center and pharmacy campus supports prescription dispensing, manufacturing, and distribution capacity.
  • MedisourceRx outsourcing facility — Los Alamitos, United States. This company-owned 503B facility compounds medications primarily for Hims & Hers customers.
  • Mesa pharmaceutical production and distribution facility — Mesa, United States. The approximately 289,000-square-foot leased facility provides capacity for pharmaceutical production, storage, dispensing, and distribution.
  • Apostrophe Pharmacy — Gilbert, United States. The approximately 25,000-square-foot pharmacy supports personalized prescription compounding and fulfillment for Hims & Hers customers.
  • Menlo Park peptide facility — Menlo Park, United States. The acquired peptide facility is intended to expand domestic ingredient manufacturing and strengthen the company's supply chain for personalized treatments.
See them on the globe

Hims & Hers Health, Inc. Form 10-K, filed 2026-02-23

How is the business doing?

Sales grew from $148.8M in 2020 to $2.3B in 2025, about 74% a year.

It still spends more to run the business than it brings in: an operating loss of 8¢ per sales dollar, narrower than 10¢ in 2020.

After paying for its upkeep and new investment, it had $8.2M of cash to spare in the 12 months to Sep 2026.

Sales$2.3B
20202025
Operating margin4%
20202025
Free cash flow$57.4M
20202025
Each bar is one fiscal year (2020–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

The company says it exists to help people feel better through improved health.

“help the world feel great through the power of better health”

2025 Form 10-K

Who is responsible for the plan?

Roles checked November 12, 2026.

What management says it is working on now:

  • Expand personalized care

    Management expects personalized offerings to increasingly drive U.S. revenue growth and plans to invest in more personalized products and compounding capabilities.

    2025 Form 10-K
  • Grow customer reach

    Management plans continued investment in marketing, customer experience and new specialties to attract customers and encourage existing customers to use more offerings.

    2025 Form 10-K
  • Expand internationally

    Management describes international growth as a core pillar, with investment in existing markets and expansion into new ones, including through the Eucalyptus acquisition.

    2025 Form 10-K
  • Build operating capabilities

    Management plans further investment in pharmacies, laboratory testing and peptide manufacturing facilities to bring more fulfillment and operations in-house.

    2025 Form 10-K
  • Use AI and technology in care

    Management says its current focus includes rebuilding the consumer health experience with a doctor-led AI clinical engine and using technology to improve efficiency and affordability.

    Q2 2026 results release
Revenue, 2026
$3.1 billion to $3.3 billion
Q2 2026 results release
Adjusted EBITDA, 2026
$275 million to $325 million
Q2 2026 results release
Revenue, 2030
At least $6.5 billion
Q2 2026 results release
Adjusted EBITDA, 2030
At least $1.3 billion
Q2 2026 results release
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is picking up. In Q3 2026 it sold 49% more than a year earlier. The year before, quarters averaged 30%.

Its operating margin is narrower than a year ago: a loss of 7¢ per sales dollar, against 2¢.

Since Oct 2026 the share price has fallen 37%, from $29.67 to $18.56.

Bull $21.96Base $10.11Bear $0.92Oct 30Nov 16 · $18.56
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Ongoing following June 2026 close

    Eucalyptus acquisition integration

    The company completed its acquisition of Eucalyptus in June 2026, expanding its presence in Australia, the UK, Germany, Canada and Japan; results may show how the combined operations perform.

    Q2 2026 results release
  • Q3 2026

    Third-quarter 2026 results

    Management expects third-quarter revenue of $880 million to $900 million and Adjusted EBITDA of $75 million to $95 million.

    Q2 2026 results release
  • Uncertain; regulatory developments ongoing

    FDA response to compounded GLP-1 products

    The FDA has stated it intends to restrict certain active ingredients used in compounded GLP-1 drugs, and the company says it is unclear what actions regulators may take.

    2025 Form 10-K

Our own estimate moved too: the base case went from $6.87 to $10.11 a share between our last two valuations. The biggest reason: Free cash flow, Q3 moved from an unreported prior value to $26.0M, as reported in Hims & Hers Q3 2026 results (8-K).

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Compounded GLP-1 rules and enforcement

    The FDA has said it intends to restrict certain ingredients used in compounded GLP-1 products, and the company was directly named. Restrictions or enforcement could disrupt products, add costs and reduce sales.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  2. Healthcare regulation

    Telehealth, pharmacy, compounding, testing and privacy rules vary and are evolving. Compliance failures or rule changes could require operational changes, raise costs or limit services.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  3. Customer acquisition and retention

    Growth depends on attracting customers through marketing and keeping subscribers. Less effective advertising, higher marketing costs or customers cancelling subscriptions could slow revenue growth.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  4. Competition

    The company competes with established healthcare providers, retailers, pharmaceutical providers and technology companies, some with greater resources. It may not compete effectively or preserve its brand advantage.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  5. Growth execution and profitability

    Rapid expansion, new offerings, facilities and acquisitions put pressure on management and operations. If these investments do not attract enough demand or are not integrated effectively, costs may rise without a matching improvement in results.

    From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K

  6. Sensitive data and security

    A security breach or misuse of customer health or contact information could interrupt operations, harm trust and lead to liability or added costs.

    From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K

  7. Subscribers fell about 100K from the prior quarter in Q3 2026.

    From our researchWould hit how fast sales growHims & Hers Q3 2026 press release

  8. FY2026 adjusted EBITDA guidance was lowered to $257M–$277M, under 9% of revenue.

    From our researchWould hit how much of each sale it keepsHims & Hers Q3 2026 results (8-K)

Is it a good business?

From 2021 to 2025 it earned between -32% and 26% on its shareholders' equity, a median of -7%.

Over 6 years its operating margin ranged from 42¢ to 4¢ per sales dollar, a median of 7¢. Gross margin ran from 74¢ to 82¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity24%
20202025
Return on invested capital is operating profit after tax (at the median effective rate, —) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 6.0% in a year, so each remaining share owns a slightly bigger slice.

It owes $761.8M more than it holds in cash. The latest four quarters had no positive operating profit to compare with that debt.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $18.56. Our put its value between $0.92 and $21.96, with $10.11 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $0.92

This scenario assumes the slowdown in new customers continues, so Hims grows only a little beyond the boost from its Australian acquisition and its recent slide into losses improves only to thin profits.

Base case, $10.11

This scenario assumes Hims keeps growing at a healthy but slowing pace after years of 60%-plus growth, and its recent losses turn back into solid profits as the company gets bigger.

Bull case, $21.96

This scenario assumes Hims's new product launches and overseas expansion bring customer growth back, so sales keep rising quickly and the company becomes much more profitable than at any point so far.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 84%

For Hims & Hers Health to be worth today's $18.56, sales would need to grow about 31.1% a year. We assume 17.4%. Over the last 5 years, sales grew 65.9% a year.

−20%0%+20%+40%+60%+80%We assume 17.4%Price needs 31.1%Past 5 yrs 65.9%

Or, if sales grow 17.4% as we assume, the price works with a profit margin of 16.3% (we assume 10.0%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 31.1% a year?

Try your own numbers

We're not very sure of this range: it scores 44 out of 100 on our checks. The weakest point is scenario dispersion.

Test the assumptions

Our base value of $10.11 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average17.4%

    Next year 31.0%, then about 14%

  • Operating margin10.0%
  • Long-term growth rate3.0%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$10.11 -45.5%

Build